The budget cuts threaten global progress on everything from heart disease to H.I.V. — and could affect American drug ...

Gilead Sciences Inc. closed 9.97% short of its 52-week high of $119.96, which the company reached on March 10th.

Gilead Sciences Inc. closed 8.32% below its 52-week high of $119.96, which the company reached on March 10th.

Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD ...

Lenacapavir, a twice-yearly HIV prevention shot by Gilead, could be produced for $25 a year but may sell for $25K, raising ...

During the first quarter, the Global Women’s Leadership portfolio lagged global developed market equities overall in the ...

The firm’s analysis suggests that high clinician engagement, lower-than-expected adherence to oral PrEP medications, and the ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Goldman Sachs analyst ...

During a live event, Chandler H. Park, MD, and participants discuss NCCN guidelines and TiNivo-2 data for second-line renal ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

At the Heart in Diabetes CME Conference, speakers highlighted four recent reports published in the Journal of the American ...

Insmed shares rocketed on results for a pulmonary arterial hypertension drug that exceeded Wall Street expectations.